Immunogen (IMGN) Tops Q1 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts IMGN Hot Sheet
Join SI Premium – FREE
Immunogen (NASDAQ: IMGN) reported Q1 EPS of ($0.10), $0.11 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $38.1 million versus the consensus estimate of $21.47 million.
GUIDANCE:
Immunogen sees FY2022 revenue of $75-85 million, versus the consensus of $85 million.
For earnings history and earnings-related data on Immunogen (IMGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- SLM (SLM) Misses Q3 EPS by 36c; lowers guidance
- First Hawaiian (FHB) Misses Q3 EPS by 7c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
